Brief: Shilpa Medicare Announces Successful Completion Of Early Clinical Development And Ongoing Phase 3 Clinical Trial Of Drug Sml-007
14/05/2024 16:27
May 14 (Reuters) - Shilpa Medicare Ltd SHME.NS :
* ANNOUNCES SUCCESSFUL COMPLETION OF EARLY CLINICAL
DEVELOPMENT
AND ONGOING PHASE 3 CLINICAL TRIAL OF DRUG SML-007
* PHASE 3 CLINICAL STUDY DOSING IS EXPECTED TO BE COMPLETED
BY END
OF Q1, STUDY IS LIKELY TO BE CONCLUDED BY Q2 END
Source text for Eikon: ID:nNSE3rbwNj
Further company coverage: SHME.NS
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Shilpa Medicare
See all newsBrief: Shilpa Medicare Q2 Consol Net Profit INR 791.8 Million
Brief: Shilpa Medicare Says USFDA Conducts Surveillance Inspection At Shilpa Medicare Unit
Brief: Shilpa Medicare Receives Final SEC Approval For Oeris Marketing Authorization
India's Shilpa Medicare gains on approval for OERIS
Brief: Shilpa Medicare Initiates Voluntary Recall Of 27,923 Pemetrexed Injection Vials In Us On July 29, 2026